Background: Axonal Genome Transport Body Atrophy and Bottleneck in Structural Junction Data of CMT2A R&D

Existing linear/static molecular analyses and conventional clinical standard guidelines have critical blind spots in precisely controlling the extreme spatio-temporal heterogeneity inherent in induced pluripotent stem cell (iPSC)-derived motor neuron models or in vivo mouse axonal degeneration models. In particular, the cellular dissociation-induced structural collapse noise generated during peripheral nerve biopsies has hindered the elucidation of the rate-limiting correlations, such as the fine spatial geometric disruption of the endoplasmic reticulum-mitochondria contact site (MAM) due to MFN2 mutations, the resulting calcium flux dysregulation, and the depletion of mitochondrial transport to the axonal terminal. This lack of feedback flux and multidimensional omics dynamics landscape prevents the pre-simulation of the effective expression baseline of new drug candidates, ultimately acting as a key R&D genetic data bottleneck that leads to failure in achieving in vivo efficacy and axonal survival at the intended dosage.

Discovery: AAV-Mediated MFN2 Gene Function Restoration and Demonstration of Cell-Resolution Independent Variable Tensor Synchronization in Peripheral Axons

In this R&D center, we activated a single-cell resolution computational multi-omics independent variable tensor synchronization system to precisely analyze the dynamic restoration of mitochondrial inner and outer membrane junctions and MAMs during AAV-MFN2-mediated axonal function restoration. We tracked the free energy change at protein-protein binding interfaces using a three-dimensional molecular dynamics model to precisely predict intermolecular binding free energy in silico and proactively calculated ligand-receptor dissociation rate constants based on differential equations. In the analysis process, multidimensional sequencing technical noise and batch effects were completely eliminated using in silico algorithms, achieving a precision that surpasses existing simple biomarker-based screening techniques. This architecture perfectly maps the topological node dynamic changes of the downstream transcriptome network after gene recovery, demonstrating the molecular biological integrity of axonal neural network cytoskeleton reconstruction.

Establishment of a Model for Fine-Tuning the Endoplasmic Reticulum-Mitochondria Contact Site Structure and Reversible Homeostasis

This platform establishes a robust precision stratification model by extracting individual patient pathological subtypes and genetically distinct molecular phenotypes based on a large-scale multidimensional multi-omics matrix big data set, including pre-existing genomic, transcriptomic, and metabolomic data. To address the imbalance in mitochondrial fusion dynamics, we activated an up-clamping and down-clamping computational simulation system to fine-tune the binding rate constant and expression level of calcium influx channel proteins at the MAM junction in silico. This establishes a robust molecular physical control backbone that allows cells to reversibly restore homeostasis and flexibly maintain peripheral nerve metabolic flux even under abnormal microenvironmental stimuli such as severe oxidative stress and high calcium load, achieving a significant qualitative improvement in therapeutic efficacy.

Prospects: Establishing a Programmable Neurodegenerative Disease Treatment Standard and Activating a Next-Generation IND Digital Governance System

This fusion biology architecture completely resets the R&D governance for CMT2A gene therapy from the past static and retrospective symptomatic clinical design to a multidimensional tensor-based, predictable, and tunable programmable infrastructure. In the joint pipeline development stage with global big pharma (e.g., Voyager Therapeutics) and biotech companies, we complete a computational moat by automatically linking the cell genetic gradient correction coefficient to the model, thereby eliminating batch-to-batch variations that occur during bioreactor scale-up. This perfectly meets the companion diagnostic (CDx) digital standards of regulatory agencies such as the U.S. FDA and will serve as a leading master digital asset that drastically shortens the timeline for clinical trial protocol (IND) approval and cGMP production processes based on a computer-validated model.